Supernus Pharmaceuticals ...

NASDAQ: SUPN · Real-Time Price · USD
42.95
0.26 (0.61%)
At close: Aug 18, 2025, 3:59 PM
42.99
0.09%
After-hours: Aug 18, 2025, 04:10 PM EDT

Supernus Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
661.82M 607.52M 667.24M 579.77M
Cost of Revenue
77.91M 83.78M 87.22M 75.06M
Gross Profit
583.91M 523.74M 580.02M 504.71M
Operating Income
81.67M -5.27M 67.3M 86.03M
Interest Income
16.2M 10.45M 21.69M 10.57M
Pretax Income
97.87M 2.77M 60.74M 73.17M
Net Income
73.86M 1.32M 60.71M 53.42M
Selling & General & Admin
321.58M 336.36M 377.22M 304.76M
Research & Development
108.8M 91.59M 74.55M 90.47M
Other Expenses
71.87M 101.06M 82.63M 29.99M
Operating Expenses
502.25M 529.01M 534.4M 425.21M
Interest Expense
n/a 2.42M 7.07M 23.42M
Selling & Marketing Expenses
88.5M 99.7M 267.79M 199.71M
Cost & Expenses
580.15M 612.79M 621.62M 500.28M
Income Tax Expense
24M 1.45M 32K 19.75M
Shares Outstanding (Basic)
55.1M 54.54M 53.67M 53.1M
Shares Outstanding (Diluted)
55.96M 55.51M 61.68M 54.36M
EPS (Basic)
1.34 0.02 1.13 1.01
EPS (Diluted)
1.32 0.02 1.04 0.98
EBITDA
178.28M 90.04M 153.44M 129.19M
EBIT
97.87M 5.18M 67.81M 96.6M
Depreciation & Amortization
80.41M 84.86M 85.63M 32.59M